VNA
ACAD icon

Valley National Advisers’s Acadia Pharmaceuticals ACAD Stock Holding History

Valley National Advisers’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$12K Buy
550
+100
+22% +$2.39K ﹤0.01% 567
2025
Q4 		$12K Hold
450
– – ﹤0.01% 559
2025
Q3 		$9K Buy
450
+150
+50% +$3.55K ﹤0.01% 569
2025
Q2 		$6K Buy
300
+40
+15% +$744 ﹤0.01% 629
2025
Q1 		$4K Hold
260
– – ﹤0.01% 654
2024
Q4 		$4K Buy
+260
New +$4.2K ﹤0.01% 634

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Valley National Advisers's ACAD Position: Q1 2026 in Review

Valley National Advisers increased its Acadia Pharmaceuticals (ACAD) stake by 22% in Q1 2026, buying an estimated $2.39K and bringing the position to 550 shares worth $12K. The position accounts for ﹤0.01% of the portfolio, ranked #567.

Valley National Advisers first reported a position in ACAD in Q4 2024 and has held it in 6 quarters since. 340 funds tracked by Wall St. Rank hold ACAD as of Q1 2026.

  • Valley National Advisers held 550 shares of Acadia Pharmaceuticals worth $12K as of Q1 2026.
  • Valley National Advisers bought 100 Acadia Pharmaceuticals shares in Q1 2026, an estimated $2.39K.
  • Acadia Pharmaceuticals made up ﹤0.01% of Valley National Advisers's portfolio in Q1 2026, its #567 holding.
  • Valley National Advisers first reported a position in Acadia Pharmaceuticals in Q4 2024 and has held it in 6 quarters since.
  • 340 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q1 2026.

Based on Valley National Advisers's 13F filing for Q1 2026, filed 15 Apr 2026.